Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4889-4897

  Yu, Zhenkun ^a,b   Chan, Mei Ki ^a   O Charoenrat, Pornchai ^a   Eisenberg, David P ^a   Shah, Jatin P ^a   Singh, Bhuvanesh ^a   Fong, Yuman ^a   Wong, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; MATRIGEL; NECTIN 1; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL ADHESION; CELL INVASION; CELL JUNCTION; CELL LINE; CELL MIGRATION; CELL STRAIN MG1; CELL STRAIN MG2; CELL STRAIN MG3; CELL STRAIN MG4; CELL STRAIN SCC7; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HERPES SIMPLEX VIRUS; IMMUNOFLUORESCENCE MICROSCOPY; INVASIVE CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; NEOPLASM INVASIVENESS; SIMPLEXVIRUS; TIME FACTORS; VERO CELLS;

EID: 27644479547     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0309     Document Type: Article

References (31)

1. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
2. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-85.
3. Kooby D, Carew JF, Halterman MW, et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999;13:1325-34.
4. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10:2237-43.
5. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimbaer KL. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 2000;6:3342-53.
6. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999;10:3013-29.
7. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H, Fong Y. Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 2000;4:580-8.
8. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001;193:12-21.
9. Yu Z, Eisenberg DP, Singh B, Shah JP, Fong Y, Wong RJ. Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer 2004;112:525-32.
10. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
11. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
12. Fong Y, Kemeny N, Jarnagin W, et al. Phase 1 study of a replication-competent herpes simplex oncolytic virus for treatment of hepatic colorectal metastases[abstract 27]. Am Soc Clin Oncol Ann Meeting 2002.
13. Wong RJ, Chan MK, Yu Z, et al. Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004;10:251-9.
14. Stiles BM, Bhargava A, Adusumilli PS, et al. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer. Surgery 2003;134:357-64.
15. Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999;10:1599-606.
16. Spear PG. Herpes simplex viruses: receptors and ligands for cell entry. Cell Microbiol 2004;6:401-10.
17. Krummenacher C, Baribaud F, Ponce de Leon M, et al. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 2004;322:286-99.
18. Takai Y, Irie K, Shimizu K, Sakisaka T, Ikeda W. Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci 2003;94:655-67.
19. Beavon IR. The E-cadherin-catenin complex in tumour metastasis: structure, function, and regulation. Eur J Cancer 2000;36:1607-20.
20. Yoon M, Spear PG. Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J Virol 2002;76:7203-8.
21. Wong RJ, Patel SG, Kim SH, et al. Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 2001;12:253-65.
22. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to sites of lymphatic metastases. Hum Gene Ther 2002;13:1213-23.
23. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-14.
24. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990;162:313-21.
25. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983;64:313-20.
26. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988;115:61-9.
27. Levaditi C, Nicolau S. Affinité du virus herpétique pour les néoplasms épithéliaux. C R Soc De Biol 1922;86:498-500.
28. Moore A. Effect of inoculation of the viruses of influenza A and herpes simplex on the growth of transplantable tumors in mice. Cancer 1949;2:516-24.
29. Kawakatsu T, Shimizu K, Honda T, Fukushara T, Hoshino T, Takai Y. Trans-interactions of nectins induce formation of filopodia and lamellipodia through the respective activation cdc42 and rac small g proteins. J Biol Chem 2002;277:50749-55.
30. Ikeda W, Kakunaga S, Takekuni K, et al. Nectin-like molecule-5/tage4 enhances cell migration in an integrin-dependent, nectin-3-independent manner. J Biol Chem 2004;279:18015-25.
31. Takai Y, Nakanishi H. Nectin and afadin: novel organizers of intercellular junctions. J Cell Sci 2003;116:17-27.